Tomásia Oliveira de Holanda Monteiro Frezatti

Ms. Tomásia Oliveira de Holanda Monteiro Frezatti

orcid

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 October 2026 in Epileptic Disorders
Verified
Journal Article
Open access
PDF file
TFTomásia Oliveira de Holanda Monteiro Frezatti
Tomásia Oliveira de Holanda Monteiro Frezatti
RSRicardo L. Saute
Ricardo L. Saute
VJVeriano Alexandre Júnior
Veriano Alexandre Júnior
FNFrederico N. Nakano
Frederico N. Nakano
MDMarina T. R. P. Dalio
Marina T. R. P. Dalio
ASAmérico C. Sakamoto
Américo C. Sakamoto
Objective: To evaluate the feasibility of investigating autoimmune etiology in adults with drug‐resistant epilepsy (DRE) of unknown origin in resource‐limited settings and to develop a pragmatic, hypothesis‐generating screening approach to guide autoantibody testing. Methods: A prospective observational study including adults with DRE of unknown etiology was conducted at a tertiary epilepsy center in Brazil. All patients underwent standardized assessment including inflammatory and autoimmunity markers, brain magnetic resonance imaging (MRI), electroencephalography (EEG), cerebrospinal fluid (CSF) analysis, and application of the APE2 and ACES scores. Clinical, laboratory, and imaging findings were analyzed in the context of published autoimmune‐associated epilepsy (AAE) profiles to inform a pragmatic screening strategy. Results: Twenty‐six patients (46.2% female; median epilepsy duration: 18.5 years) were included. EEG findings were nonspecific. Six patients developed mesial temporal abnormalities on follow‐up MRI. CSF protein elevation was observed in 37.5%, oligoclonal bands in 13.6%, and elevated IgG index in 18.2%. Antinuclear antibodies were detected in 26.9%. APE2 score ≥ 4 was present in 57.7%, while ACES score ≥ 2 occurred in 11.5%. Due to limited access to antibody testing, only one patient underwent CSF autoantibody analysis, confirming high‐titer anti‐GAD65. Based on integrated clinical, laboratory, and imaging findings, a pragmatic screening algorithm was proposed to prioritize candidates for autoantibody testing. Significance: In resource‐limited settings, systematic use of accessible clinical and laboratory markers may help identify patients with higher pre‐test probability of AAE. A pragmatic screening approach may improve diagnostic efficiency and support individualized decision‐making when comprehensive antibody testing is not readily available.

Verified
Journal Article
Open access
PDF file
TFTomásia Oliveira de Holanda Monteiro Frezatti
Tomásia Oliveira de Holanda Monteiro Frezatti
Leonardo RoeverLeonardo Roever
Leonardo Roever
OPOctávio Pontes-Neto
Octávio Pontes-Neto
Stroke is a major cause of acquired epilepsy in adults, particularly in older individuals. However, seizures after stroke should not be regarded as a single clinical entity. Acute symptomatic seizures (ASyS) occur within the first seven days after stroke and are considered provoked events, whereas remote symptomatic seizures carry a higher recurrence risk and may fulfill the practical definition of post-stroke epilepsy (PSE). This narrative review provides a clinically oriented synthesis of current evidence on definitions, epidemiology, pathophysiology, risk factors, predictive scores, EEG and biomarker-based risk stratification, seizure prevention, and antiseizure medication (ASM) management. Current evidence does not support routine primary antiseizure medication prophylaxis for all stroke patients. In contrast, documented clinical or electrographic seizures require appropriate treatment, and established PSE often requires long-term individualized therapy. Predictive tools may help guide surveillance, EEG indication, counseling, and follow-up, but should not be used as automatic triggers for prophylactic treatment. ASM choice should account for seizure type, age, comorbidities, cognitive and psychiatric vulnerability, drug interactions, and secondary vascular prevention. Future research should focus on validated biomarkers and preventive strategies capable of modifying epileptogenesis after stroke.


18 June 2026 in Epileptic Disorders
Verified
Journal Article
Closed access
TFTomásia Oliveira de Holanda Monteiro Frezatti
Tomásia Oliveira de Holanda Monteiro Frezatti
RSRicardo Lutzky Saute
Ricardo Lutzky Saute
VSVanessa Launna Lima Silva
Vanessa Launna Lima Silva
JAJoão Marcus de Lima Brito Alves
João Marcus de Lima Brito Alves
LSLucas Emmanuel Lopes e Santos
Lucas Emmanuel Lopes e Santos
ASAmérico Ceiki Sakamoto
Américo Ceiki Sakamoto

12 May 2026 in Arquivos de Neuro-Psiquiatria
Verified
Journal Article
Open access
TFTomásia Oliveira de Holanda Monteiro Frezatti
Tomásia Oliveira de Holanda Monteiro Frezatti
VMVanessa Daccach Marques
Vanessa Daccach Marques
ASAmérico Ceiki Sakamoto
Américo Ceiki Sakamoto
Autoimmune-associated epilepsy (AAE) is an increasingly-recognized condition in which seizures result from immune-mediated mechanisms, such as Rasmussen's encephalitis and antibody-associated epilepsies. Its timely identification may enable more efficacious therapy and improve outcomes. The current paper aims to provide a clinically-oriented review of AAE, focusing on clinical identification, use of diagnostic scoring systems, and immunological testing strategies. Antibody-associated epilepsy encompasses a broad spectrum of presentations, from postencephalitic epilepsy to isolated drug-resistant temporal-lobe epilepsy. Neuronal-surface autoantibodies (such as anti-N-methyl-D-aspartate receptor (anti-NMDAR), anti- leucine-rich glioma-inactivated protein 1 (anti-LGI1), anti-CASPR2) and intracellular antibodies (such as anti-GAD65) are variably associated with pathogenesis and chronicity. Clinical scoring systems (such as Antibody Prevalence in Epilepsy and Encephalopathy - APE2, Antibody Contributing to Focal Epilepsy Signs and Symptoms - ACES, ntibody Prevalence in Epilepsy before Surgery - APES, Antibody in Drug-Resistant Temporal Lobe Epilepsy - ARTE and ‘Obvious’ Indications for Neural Antibody Testing in Epilepsy or Seizures - ONES) are helpful in selecting patients for autoantibody testing. A comprehensive workup includes magnetic resonance imaging (MRI) scans, prolonged electroencephalographic (EEG) monitoring, cerebrospinal fluid (CSF) analysis, and combined serum/CSF antibody panels. Testing methodology and antibody type must be carefully interpreted in the light of clinical context. In low-resource settings, cost-effective testing strategies and clinical-screening tools are crucial to optimize the diagnostic yield. Early clinical suspicion, guided use of diagnostic scores, and appropriate immunological investigation are central to manage AAE. Recognizing AAE as a distinct diagnostic category is essential to improve care and guide immunotherapeutic decisions.